Lapam Capital

Active

Website LinkedIn

Updated: Apr 1, 2026 ·

Financial History

Total Raised

N/A

Valuation

N/A

Investments Made

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Dec 19, 2025	Ningkang Ruizhu	$20.0M Series A	Lapam Capital	Riverhead Capital
Dec 16, 2025	Allink Biotherapeutics	$47.0M Series A Extension	郭学婧, Tan Hong	5Y Capital
Nov 25, 2025	Phrontline Biopharma	$60.0M Pre-Series A	王及	Decheng Capital, Med-Fine Capital, Samsung, Sino Biopharmaceutical
Oct 16, 2025	BridGene Biosciences	$28.0M Series B	Yuexing Su	Grains Valley Venture Capital, GTJA Investment Group, Proxima Ventures
Sep 30, 2025	Full-Life Technologies	$77.0M Life Technologies - Debt / Series C	Wei Shen	Chengwei Capital, Plaisance Capital Management, Prosperity7 Ventures, Sequoia Capital, Summer Capital, TruMed Investment
Sep 8, 2025	Rapafusyn Pharmaceuticals	$44.0M Series A	—	Karen Liu, Jian Li, Haolin Sung, Wen Chen
Sep 1, 2025	Epigenic Therapeutics	$60.0M Series B	Zhihua Yu	OrbiMed, IFSC, Qiming Venture Partners
May 1, 2025	EnChannel Medical	$83.9M Series B	DragonBall Capital, Lilly Asia Ventures	—
Jul 1, 2024	ReviR Therapeutics	$30.0M Series A	Lapam Capital	5Y Capital
Jul 1, 2024	LTZ Therapeutics	$20.0M Series A	Lapam Capital	Qiming Venture Partners
Jun 24, 2024	Rapafusyn Pharmaceuticals	$28.0M Series A	Karen Liu, Proxima Ventures	Zhihua Yu
May 25, 2023	DeepKinase	$14.2M Series A Extension	Zhihua Yu	Feifan Venture Capital, Fengrui Capital, Zhongguancun Development Group
Oct 3, 2022	NeuShen Therapeutics	$20.0M Pre-Series A	Zhihua Yu	—
Jul 28, 2022	BridGene Biosciences	$38.5M Series B	Dyee Capital, Junson Capital, Lapam Capital	—
Jun 13, 2022	First Technology	$100.0M Series C	—	Cherami Investment Group, Jintan Capital
Oct 12, 2021	Chance Pharmaceuticals	$30.0M Series C	Zhihua Yu	Guozhong Capital, HEDA BioVenture
Aug 18, 2021	Ranok Therapeutics	$40.0M Series B	Zhihua Yu, Hong Wen	Wu Capital, Zhongguancun Kaiyuan Capital
Sep 29, 2020	Hugo Biotech	$32.0M Series A	Lapam Capital, Lee Kai-Fu	—
Nov 28, 2019	Clover Biopharmaceuticals	$43.3M Series B	Tim Xiao, Guangyu Xu	—
Dec 28, 2017	Asieris Pharmaceuticals	$15.0M Series B	Zhihua Yu	—
Nov 15, 2017	Cygnus Biosciences	$19.6M Other Equity	Lu Zhang, Long Yibin	Jingming BAO, Jinggong Hongyuan, Zhihua Yu, Star Ventures
May 1, 2017	CANbridge Pharmaceuticals	$25.0M Series B	Lapam Capital	Qiming Venture Partners, Biossom Investment Management, Haoyue Capital, WuXi AppTec, Yanyuan Capital, YuanMing Capital
Jan 1, 2017	Connect Biopharmaceuticals	$20.0M Series A	Qiming Venture Partners	Co-win Ventures, Northern Light Venture Capital
Jan 1, 2014	Insgeek	$16.5M Series B	—	Legend Holdings